Does metoprolol CR improve ventricular function, reduce activation of the renin-angiotensin systems, and prevent deaths in patients with ischemic and dilated cardiomyopathy?
Metoprolol CR provides mortality and physiological benefits in patients with ischemic and dilated cardiomyopathy already receiving ACE inhibitors or ARBs.
When added to ACE inhibitors, angiotensin II receptor antagonists, or both, the use of metoprolol CR improves ventricular function, reduces activation of the renin-angiotensin systems, and results in fewer deaths.
A Tue, study studied this question.